From bench to bedside and back again?

June 2004
CMAJ: Canadian Medical Association Journal;6/8/2004, Vol. 170 Issue 12, p1765
Academic Journal
Comments on the concept of studying a small subset of patients in line with a clinical study involving nine patients with non-small-cell lung cancer who responded to the drug gefitinib. Information on gefitinib, a chemotherapeutic agent; Impact of the concept on large, population-based multicenter randomized clinical trials; Overview of the ethical issues that may arise from the concept of studying a small subset of patients.


Related Articles

  • Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials. Gerber, David E.; Laccetti, Andrew L.; Lei Xuan; Halm, Ethan A.; Pruitt, Sandi L. // JNCI: Journal of the National Cancer Institute;Nov2014, Vol. 106 Issue 11, p1 

    Background In oncology clinical trials, the assumption that a prior cancer diagnosis could interfere with study conduct or outcomes results in frequent exclusion of such patients. We determined the prevalence and characteristics of this practice in lung cancer clinical trials and estimated...

  • Clinical Trial Results Applied to Management of the Individual Cancer Patient. Jatoi, Ismail; Proschan, Michael A. // World Journal of Surgery;Jul2006, Vol. 30 Issue 7, p1184 

    The application of clinical trial results to the management of the individual cancer patient is not always straightforward. The results of a clinical trial indicate the “average” effect of an intervention, often expressed in terms of an absolute risk reduction, which is an estimate...

  • Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. Murthy, Vivek H.; Krumholz, Harlan M.; Gross, Cary P. // JAMA: Journal of the American Medical Association;6/9/2004, Vol. 291 Issue 22, p2720 

    Context Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective To characterize the representation of racial and ethnic minorities, the...

  • Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Crott, Ralph; Briggs, Andrew // European Journal of Health Economics;Aug2010, Vol. 11 Issue 4, p427 

    Although cancer-specific Health-Related Quality of Life (HRQOL) are commonly included in randomized clinical trials or other prospective non-randomized clinical studies, it is rare that preference-based instruments are used that allow the calculation of a utility weight suitable for estimating...

  • Impact of Cultural and Linguistic Factors on Symptom Reporting by Patients With Cancer. Wang, Xin Shelley; Cleeland, Charles S.; Mendoza, Tito R.; Young Ho Yun; Ying Wang; Okuyama, Toru; Johnson, Valen E. // JNCI: Journal of the National Cancer Institute;5/19/2010, Vol. 102 Issue 10, p732 

    Background: Patient reporting of the severity and impact of symptoms is an essential component of cancer symptom management and cancer treatment clinical trials. In multinational clinical trials, cultural and linguistic variations in patient-reported outcomes instruments could confound the...

  • The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. Colin Newman; Gregory Pond // Supportive Care in Cancer;Jul2007, Vol. 15 Issue 7, p829 

    Abstract Goals of work  The quality of informed consent in phase I trials is controversial, partially due to gaps in patient understanding. We assessed an educational DVD’s impact on knowledge and satisfaction in cancer patients newly referred to a phase I clinic. Materials and...

  • Access to Drugs for Cancer: Does Where You Live Matter? Menon, Devidas; Stafmnski, Tania; Stuart, Gavin // Canadian Journal of Public Health;Nov/Dec2005, Vol. 96 Issue 6, p454 

    Background: Provincial governments are responsible for administering publicly-funded anti-cancer drug benefit programs in Canada. This study examines inter-provincial variations in not only the content of such programs, but also the policies/processes used when considering a new drug for...

  • A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials. Goffin, John R.; Pond, Greg R.; Tu, Dongsheng // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p95 

    Background: Response rate (RR) alone may be insensitive to drug activity in phase II trials. Early progressive disease (EPD) could improve sensitivity as well as increase stage I stopping rates. This study compares the previously developed dual endpoint stopping rule (DESR), which incorporates...

  • Contributing to Applied Clinical Trials.  // Applied Clinical Trials;Aug2006, Vol. 15 Issue 8, p82 

    The article invites authors to contribute papers and manuscripts relevant to applied clinical trials. Appropriate topics include preparing protocols, consent documents, recruiting and working with human subjects, collecting and managing data, dealing with ethical issues, optimizing business...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics